What is the Best Injection for Weight Loss?

How to Choose the Right Weight Loss Injection for You

When choosing an injectable weight loss medication, there are plenty of options to consider. Across the board, injectable GLP-1 RA medications are highly effective in promoting weight loss. However, keep in mind that the numbers mentioned are averages. Everyone’s experience can be different – some might lose more weight, while others might lose less. Sometimes, people find the right medication for them right away, but others might need to try different ones for reasons like how well it works, how they tolerate it, side effects, or insurance coverage. A licensed healthcare professional is essential to guide you through your weight loss journey. 

Mochi Health, a leading obesity medicine practice, offers access to these medications through our team of board-certified physicians. Our tailored approach is personalized and grounded in scientific evidence, empowering patients to achieve sustainable weight loss and improve their overall health. At Mochi Health, our team of medical professionals and obesity medicine experts ensures that every patient receives personalized care and access to the most effective and suitable medications delivered directly to their door.

Whether you plan to use insurance or pay out-of-pocket, Mochi Health offers flexible plans and affordable alternatives to accommodate your financial situation and health objectives.

Choosing a weight loss injection is a significant step toward achieving your health goals. Under the guidance of the experts at Mochi Health, you'll receive the support, knowledge, and medical assistance needed to make informed choices about your wellness journey. Find out if you’re eligible for the program and get started today.

References:

1. Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., Woo, V., Hansen, O., Holst, A. G., Pettersson, J., & Vilsbøll, T. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141

2. Jastreboff, A. M., Aronne, L. J., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. Reply. The New England Journal of Medicine, 387(15), 1434–1435. https://doi.org/10.1056/NEJMc2211120

3. Jastreboff, A. M., Aronne, L. J., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. Reply. The New England Journal of Medicine, 387(15), 1434–1435. https://doi.org/10.1056/NEJMc2211120

4. Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA : The Journal of the American Medical Association, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619

5. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

6. Seino, Y., Fukushima, M., & Yabe, D. (2010). GIP and GLP‐1, the two incretin hormones: Similarities and differences. Journal of Diabetes Investigation, 1(1‐2), 8–23. https://doi.org/10.1111/j.2040-1124.2010.00022.x

7. Muzurović, E. M., Volčanšek, Š., Tomšić, K. Z., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 27, 10742484221146371–10742484221146371. https://doi.org/10.1177/10742484221146371

8. Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021). The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes, Obesity & Metabolism, 23(S3), 5–29. https://doi.org/10.1111/dom.14496

This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.